Acuta Capital Partners, LLC Mirati Therapeutics, Inc. Transaction History

Acuta Capital Partners, LLC

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$59.5 - $86.7 $612,850 - $893,010	10,300 Added 10.9%	104,800 $7.32 Million
Q2 2022 Aug 15, 2022	BUY	$39.16 - $88.71 $1.64 Million - $3.73 Million	42,000 Added 80.0%	94,500 $6.34 Million
Q1 2022 May 16, 2022	BUY	$75.82 - $150.97 $2.46 Million - $4.91 Million	32,500 Added 162.5%	52,500 $4.32 Million
Q4 2021 Feb 14, 2022	BUY	$132.01 - $190.29 $2.64 Million - $3.81 Million	20,000 New	20,000 $2.93 Million
Q2 2021 Aug 16, 2021	SELL	$144.0 - $179.73 $1.3 Million - $1.62 Million	-9,000 Closed	0 $0

Q1 2021 May 17, 2021	BUY	$158.92 - $221.61 $1.43 Million - $1.99 Million	9,000 New	9,000 $1.54 Million
Q4 2019 Feb 14, 2020	SELL	$70.76 - $128.86 $1.2 Million - $2.19 Million	-17,000 Closed	0 $0
Q3 2019 Nov 14, 2019	SELL	$77.91 - $109.6 $3.54 Million - $4.99 Million	-45,500 Reduced 72.8%	17,000 $1.32 Million
Q2 2019 Aug 14, 2019	BUY	$59.49 - $104.71 $1.28 Million - $2.25 Million	21,500 Added 52.44%	62,500 $6.44 Million
Q1 2019 May 14, 2019	BUY	$43.65 - $78.95 $1.79 Million - $3.24 Million	41,000 New	41,000 $3.01 Million
Q2 2018 Aug 15, 2018	SELL	$26.05 - $52.4 $2.61 Million - $5.24 Million	-100,000 Closed	0 $0
Q1 2018 May 15, 2018	SELL	$17.2 - $34.95 $946,000 - $1.92 Million	-55,000 Reduced 35.48%	100,000 $3.07 Million
Q4 2017 Feb 14, 2018	BUY	$12.65 - $19.0 $1.96 Million - $2.95 Million	155,000	155,000 $2.83 Million

3.57M

36.6K

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

Get notified when there are updates to the investment portfolio of Acuta Capital Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Acuta Capital Partners, LLC with notifications on news.